The Medicines and Healthcare products Regulatory Agency (MHRA) has approved depemokimab (Exdensur, GSK plc) as add-on therapy for severe asthma and for chronic rhinosinusitis with nasal polyps (CRSwNP ...
To claim CE credit for this activity, please visit https://www.pharmacytimes.org/courses/emerging-care-management-strategies-for-severe-asthma-integrating-biologic ...
Following the recent update to the National Institute of Care Excellence (NICE) guidelines for asthma care and management, Bedfont ® Scientific Limited sponsored an informative webinar by Intermedical ...
A monthly injection could enable severe asthma patients to stop taking daily steroid tablets without affecting their symptoms, a new trial has found. The drug, Tezepelumab (also known as Tezspir and ...
Depemokimab 'has the potential to redefine care for millions of patients' A ‘LIFE-SAVING’ jab for severe asthma that could prevent deadly attacks with just two doses a year could be available to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results